References
- 1. DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology. 2009; 49:1729–1764.
- 2. Rubbia-Brandt L. Sinusoidal Obstruction Syndrome. Clin Liver Dis. 2010; 14:651–668.10.1016/j.cld.2010.07.009
- 3. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002; 22:27–42.
- 4. Valla D-C, Cazals-Hatem D. Sinusoidal obstruction syndrome. Clin Res Hepatol Gastroenterol. 2016; 40:378-385.10.1016/j.clinre.2016.01.006
- 5. Lin G, Wang JY, Li N, Li M, Gao H, Ji Y, Zhang F, et al. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol. 2011; 54:666-67.2114689410.1016/j.jhep.2010.07.031
- 6. Adam R. Colorectal cancer with synchronous liver metastases. Br J Surg. 2007; 94:129–131.
- 7. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup Trial 40983): a randomized controlled trial. Lancet. 2008;371:1007–1016.
- 8. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict longterm survival. Ann Surg. 2004; 240:644–657.
- 9. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET) Ann Surg. 2004; 240:438–447.
- 10. Rubbia Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460–466.
- 11. Fernandez FG, Ritter JJ, Goodwin W, Linehan DC, Hawkins WG, Strasberg SM. Effect of Steatohepatitis Associated with Irinotecan or Oxaliplatin Pretreatment on Resectability of Hepatic Colorectal Metastases. J Am Coll Surg 2005; 200: 845-853.
- 12. Milićević M, Bulajić P, Žuvela M, Dervenis C, Basarić D, Galun D. A Radiofrequency-Assisted Minimal Blood Loss Liver Parenchyma Dissection Technique. Dig Surg 2007; 24:306–313.
- 13. Rubbia-Brandt L, Lauwers G Y, Wang H, Majno P E, Tanabe K, Zhu A X, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010; 56:430–439.10.1111/j.1365-2559.2010.03511.x
- 14. Aloia T, Sebagh M, Plasse M, Karam V, Lévi F, Giacchetti S, Azoulay D, Bismuth H, Castaing D, Adam R. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006; 24:4983-90.10.1200/JCO.2006.05.8156
- 15. Vreuls CP, Van Den Broek MA, Winstanley A, Koek GH, Wisse E, Dejong CH, Olde Damink SW, Bosman FT, Driessen A. Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases. Histopathology. 2012; 61:314-8.
- 16. Rubbia-Brandt L, Mentha G, Terris B. Sinusoidal obstruction syndrome is a major feature of hepatic lesions associated with oxaliplatin neoadjuvant chemotherapy for liver colorectal metastases. J Am Coll Surg. 2006; 202:199-200.
- 17. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006; 24:2065–2072.10.1200/JCO.2005.05.3074
- 18. Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives- a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015; 50:781-9.
- 19. Rubbia-Brandt L, Tauzin S, Brezault C, Delucinge-Vivier C, Descombes P, Dousset B, et al. Gene expression profiling provides insights into pathways of oxaliplatinrelated sinusoidal obstruction syndrome in humans. Mol Cancer Ther 2011; 10:687—96.
- 20. Agostini J, Benoist S, Seman M, Julie C, Imbeaud S,Letourneur F, et al. Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation. J Hepatol 2012; 56:869-76.10.1016/j.jhep.2011.10.023
- 21. Marzano C, Cazals-Hatem D, Rautou PE, Valla DC. The significance of nonobstructive sinusoidal dilatation of the liver: impaired portal perfusion or inflammatory reaction syndrome. Hepatology 2015; 62.3: 956-963.
- 22. Wang X, Qi X, Guo X. Tusanqi-related sinusoidal obstruction syndrome in china. A systematic review of the literatures. Medicine. 2015; 94:e942.
- 23. Tarantino G, Scalera A, Finelli C. Liver-spleen axis: intersection between immunity, infections and metabolism. World J Gastroenterol. 2013; 19:3534–3542.10.3748/wjg.v19.i23.3534
- 24. Imai K, Emi Y, Iyama KI, et al. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin induced hepatic sinusoidal obstruction syndrome. Eur J Surg Oncol. 2014; 40:559–566.10.1016/j.ejso.2013.12.009
- 25. Soubrane O, Brouquet A, Zalinski S, Terris B, Brézault C, Mallet V, Goldwasser F, Scatton O. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg. 2010; 251:454-60.